With a $174 million manufacturing pact signed Monday, Maryland-based Emergent BioSolutions will help produce bulk drug substance for AstraZeneca and Oxford's adenovirus-based COVID-19 shot ...

To that end, Bayer plans to make 160 million doses of the CureVac shot in 2022, with the first commercial product expected to be made available at the end of this year. The vaccine entered phase 3 ...

Manufacturing lead shot, primarily used in ammunition, was even then a fairly simple process, but it did require the construction of a tower built especially for that purpose.